Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent with a long half-life, making it suitable for single-dose or short-course therapy. It is highly effective against a broad spectrum of anaerobic bacteria and protozoa, including Giardia lamblia and Trichomonas vaginalis. Its primary advantage in the Indian context is its simplified dosing regimen, which improves patient compliance in community and outpatient settings.
Adult: Intestinal Amebiasis/Giardiasis: 2g (four 500mg tablets) as a single dose. Trichomoniasis: 2g single dose for both partners. Bacterial Vaginosis: 2g single dose. Anaerobic Infections: 1-2g as a single dose or 500mg twice daily for 5-7 days.
Note: Administer orally after meals to minimize gastrointestinal upset. Tablets should be swallowed whole with a full glass of water. For single-dose therapy, the entire prescribed dose is taken at one time.
Secnidazole is a prodrug. Its nitro group is reduced intracellularly by low-redox potential electron transport proteins (ferredoxin or flavodoxin) found in anaerobic microorganisms. This reduction generates cytotoxic intermediates that damage microbial DNA. The reduced nitro radicals form unstable compounds that cause strand breaks and loss of the helical structure of DNA, leading to inhibition of nucleic acid synthesis and cell death.
Pregnancy: Category B (as per some older classifications). However, it crosses the placenta. Use in the first trimester is contraindicated. Use in second and third trimesters only if clearly needed and benefits outweigh risks. Avoid high-dose, long-term therapy.
Driving: May cause dizziness, vertigo, or confusion. Patients should be cautioned about operating machinery or driving until their response to the drug is known.
| Warfarin and other Coumarin Anticoagulants | Secnidazole may potentiate anticoagulant effect, increasing INR and risk of bleeding. | Major |
| Disulfiram | Concurrent use may precipitate psychotic reactions; avoid combination. | Major |
| Lithium | May increase lithium levels and risk of toxicity. | Moderate |
| Cyclosporine, Tacrolimus | Potential increase in immunosuppressant levels; monitor levels. | Moderate |
| Phenobarbital, Phenytoin | May increase metabolism of secnidazole, reducing its efficacy. | Moderate |
| Alcohol | Unlike metronidazole, a disulfiram-like reaction is uncommon but not impossible; avoidance is still recommended. | Moderate |